Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced a poster presentation at ISPOR 2026 highlighting findings from a retrospective cohort study analyzing U.S. claims data from adults with fibromyalgia between April 2021 and April 2024. The presentation will feature real-world insights related to fibromyalgia treatment, following the FDA approval of TONMYA in August 2025 and its subsequent U.S. commercial launch in November 2025.
TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) is the first new treatment for fibromyalgia in more than 15 years, representing a significant advancement for patients suffering from this chronic condition. The real-world data study is expected to provide valuable insights into treatment patterns and patient outcomes, which could inform clinical practice and healthcare decision-making.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder.
In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The importance of this announcement lies in the potential impact of real-world data on the understanding and management of fibromyalgia. With TONMYA being the first new treatment in over a decade, real-world evidence could help healthcare providers optimize treatment strategies and improve patient outcomes. The presentation at ISPOR, a leading conference for health economics and outcomes research, underscores the significance of this data for the broader healthcare community.
For more information on Tonix Pharmaceuticals, visit the company's newsroom at https://ibn.fm/TNXP. The full press release is available at https://ibn.fm/A3668.
